Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2261631
Max Phase: Preclinical
Molecular Formula: C21H16F3N3O4
Molecular Weight: 431.37
Molecule Type: Small molecule
Associated Items:
ID: ALA2261631
Max Phase: Preclinical
Molecular Formula: C21H16F3N3O4
Molecular Weight: 431.37
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(OCC(F)(F)F)c1ncn2c1[C@@H]1CCCN1C(=O)c1cc(-c3ccco3)ccc1-2
Standard InChI: InChI=1S/C21H16F3N3O4/c22-21(23,24)10-31-20(29)17-18-15-3-1-7-26(15)19(28)13-9-12(16-4-2-8-30-16)5-6-14(13)27(18)11-25-17/h2,4-6,8-9,11,15H,1,3,7,10H2/t15-/m0/s1
Standard InChI Key: GQIVRYNNTCEOBX-HNNXBMFYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 431.37 | Molecular Weight (Monoisotopic): 431.1093 | AlogP: 4.14 | #Rotatable Bonds: 3 |
Polar Surface Area: 77.57 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 2.83 | CX LogP: 3.02 | CX LogD: 3.02 |
Aromatic Rings: 3 | Heavy Atoms: 31 | QED Weighted: 0.58 | Np Likeness Score: -0.87 |
1. Li X, Yu J, Atack JR, Cook JM. (2004) Development of Selective Ligands for Benzodiazepine Receptor Subtypes by Manipulating the Substituents at Positions 3- and 7- of Optically Active BzR Ligands, 13 (5): [10.1007/s00044-004-0033-7] |
Source(1):